Biopharmaceutical company Aridis Pharmaceuticals Inc (Nasdaq:ARDS) stated on Friday that its CEO, Dr Vu Truong, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" to be held on 30 June 2020 at 11:00 ET

The company said it has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening ventilator associated pneumonia (VAP) and preclinical stage antiviral mAbs.

In addition, the company's pipeline also includes AR-701 (COVID-19), a fully human mAb cocktail discovered from convalescent COVID-19 patients that are directed at multiple envelope proteins on SARS-CoV-2. AR-201 (RSV infection). The AR-201 is a fully human IgG1 mAb out-licensed preclinical programme aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).